Analytical control strategy
Phase-appropriate control strategies, specification setting and comparability assessments that anticipate regulatory expectations and stand up at review.
- Specifications
- Comparability
- Characterisation
Embedded leadership or targeted expert input — across biologics, cell & gene therapy and novel modalities, from early development to commercial filing.
Phase-appropriate control strategies, specification setting and comparability assessments that anticipate regulatory expectations and stand up at review.
Development, qualification, validation and transfer of analytical methods — robust and fit for purpose at every stage of the lifecycle.
QC frameworks, release and stability programmes, and data integrity practices for both clinical and commercial supply.
Selecting, onboarding and overseeing analytical CDMOs — keeping outsourced work on specification, on schedule and audit-ready.
Authoring and reviewing the analytical CMC sections of regulatory submissions, and preparing programmes for filing milestones and agency questions.
Deep analytical expertise across monoclonal antibodies, gene-edited cell therapies and emerging advanced therapeutics.
Every programme is different. Engagements scale from a focused review to embedded, hands-on leadership.
A focused, independent assessment of your analytical package, control strategy or submission section — with clear, actionable recommendations.
Acting as your analytical CMC & QC lead — driving strategy, delivery and CDMO oversight as part of your team for the duration you need.
Targeted help to reach a specific milestone — IND, BLA or MAA readiness, a tech transfer, or a critical comparability exercise.
Tell me where your programme is and what's coming up — we'll find the right level of support.